This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Feb 1;5(2):171-172.

doi: 10.1001/jamaoncol.2018.5503.

Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be

Primo N Lara Jr^{1

2}, Christopher P Evans^{1

3}

Affiliations

Affiliations

¹ UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California.
² Division of Hematology-Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California.
³ Department of Urologic Surgery, UC Davis School of Medicine, Sacramento, California.

PMID: 30543365
DOI: 10.1001/jamaoncol.2018.5503

Comment

Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be

Primo N Lara Jr et al. JAMA Oncol. 2019.

. 2019 Feb 1;5(2):171-172.

doi: 10.1001/jamaoncol.2018.5503.

Authors

Primo N Lara Jr^{1

2}, Christopher P Evans^{1

3}

Affiliations

¹ UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California.
² Division of Hematology-Oncology, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California.
³ Department of Urologic Surgery, UC Davis School of Medicine, Sacramento, California.

PMID: 30543365
DOI: 10.1001/jamaoncol.2018.5503

No abstract available

PubMed Disclaimer

Comment on

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Bex A, et al. JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. JAMA Oncol. 2019. PMID: 30543350 Free PMC article. Clinical Trial.

Similar articles

Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Bajic P, Flanigan RC, Joyce CJ, Clark JI. Bajic P, et al. J Urol. 2019 Mar;201(3):453-454. doi: 10.1016/j.juro.2018.09.050. J Urol. 2019. PMID: 30266335 No abstract available.
Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.
Kesch C, Black PC. Kesch C, et al. Urology. 2018 Nov;121:1-2. doi: 10.1016/j.urology.2018.07.007. Epub 2018 Aug 2. Urology. 2018. PMID: 30077538 No abstract available.
Cytoreductive nephrectomy in metastatic renal cancer - less is more.
Bex A, Haanen J. Bex A, et al. Nat Rev Clin Oncol. 2018 Oct;15(10):595-596. doi: 10.1038/s41571-018-0065-4. Nat Rev Clin Oncol. 2018. PMID: 29967447 No abstract available.
The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J, Bhindi B, Heng DYC. Graham J, et al. Curr Opin Urol. 2019 Sep;29(5):507-512. doi: 10.1097/MOU.0000000000000657. Curr Opin Urol. 2019. PMID: 31305275 Review.
Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ, Karam JA, Wood CG. Chery LJ, et al. Clin Adv Hematol Oncol. 2016 Sep;14(9):696-703. Clin Adv Hematol Oncol. 2016. PMID: 27673288 Review.

See all similar articles

Cited by

Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.
Wang Y, Zhang Y, Wang P, Fu X, Lin W. Wang Y, et al. Mol Cancer. 2020 Oct 14;19(1):149. doi: 10.1186/s12943-020-01266-7. Mol Cancer. 2020. PMID: 33054773 Free PMC article. Review.
Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle Progression, Adhesion and Invasion.
Lee M, Ham NY, Hwang CY, Jang J, Lee B, Jeong JW, Kang I, Yeo EJ. Lee M, et al. Int J Mol Sci. 2022 Aug 26;23(17):9675. doi: 10.3390/ijms23179675. Int J Mol Sci. 2022. PMID: 36077072 Free PMC article.
Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes.
Ray S, Cheaib JG, Biles MJ, Pineault KG, Johnson MH, Ged YMA, Markowski MC, Singla N, Allaf ME, Pierorazio PM. Ray S, et al. Urology. 2021 Aug;154:201-207. doi: 10.1016/j.urology.2021.03.038. Epub 2021 Apr 20. Urology. 2021. PMID: 33864855 Free PMC article.
circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma.
Li W, Yang FQ, Sun CM, Huang JH, Zhang HM, Li X, Wang GC, Zhang N, Che JP, Zhang WT, Yan Y, Yao XD, Peng B, Zheng JH, Liu M. Li W, et al. Theranostics. 2020 Mar 15;10(10):4395-4409. doi: 10.7150/thno.43239. eCollection 2020. Theranostics. 2020. PMID: 32292503 Free PMC article.
Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma.
Lin WY, Lin MH, Yang YH, Chen WC, Huang CE, Chen MF, Wu CT. Lin WY, et al. Front Surg. 2022 May 26;9:903123. doi: 10.3389/fsurg.2022.903123. eCollection 2022. Front Surg. 2022. PMID: 35693310 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information